Archive: 2026/02 - Page 2

Immunosuppressant Generic Issues: Cyclosporine vs Tacrolimus Risks and Solutions
Marian Andrecki 10

Immunosuppressant Generic Issues: Cyclosporine vs Tacrolimus Risks and Solutions

Exploring the risks and challenges of generic cyclosporine and tacrolimus for transplant patients. Learn why bioequivalence issues, dosing differences, and switching protocols matter for safety and effectiveness.

Read More
How to Manage Medication Costs During Medicare Part D Coverage Gaps (Donut Hole) in 2024-2025
Marian Andrecki 12

How to Manage Medication Costs During Medicare Part D Coverage Gaps (Donut Hole) in 2024-2025

Learn how to cut prescription costs during Medicare Part D’s donut hole in 2024 before the $2,000 out-of-pocket cap eliminates it in 2025. Proven strategies for saving hundreds or thousands on meds.

Read More
SGLT2 Inhibitors for Type 2 Diabetes: What You Need to Know About Benefits and Risks
Marian Andrecki 12

SGLT2 Inhibitors for Type 2 Diabetes: What You Need to Know About Benefits and Risks

SGLT2 inhibitors help lower blood sugar and protect the heart and kidneys in type 2 diabetes, but come with risks like yeast infections and rare but serious ketoacidosis. Know who benefits most and what to watch for.

Read More
Salt Substitutes and ACE Inhibitors or ARBs: Hidden Potassium Risks
Marian Andrecki 14

Salt Substitutes and ACE Inhibitors or ARBs: Hidden Potassium Risks

Salt substitutes with potassium chloride can cause dangerous potassium buildup when taken with ACE inhibitors or ARBs, especially for people with kidney disease. Learn who’s at risk and what safer alternatives exist.

Read More